Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Synosis: the Financial Leverage of Translational Medicine

This article was originally published in Start Up

Executive Summary

Biotech investors have struggled with the fact that it takes take years, hundreds of millions of dollars, and widely varying sets of expertise to create a product. For Synosis, the answer is translational medicine: it starts life with nine compounds from three European companies, aiming to figure out the best indications and dosing for each, prove them through Phase II, and then out-license them.

Related Content

Synosia Reworks Roche Deal To Take On Alzheimer’s/Schizophrenia Candidate
Biopharma: Reviewing 2007 to Forecast 2008
Public Venture Capital for Israel's Biotech Industry
Lilly's Chorus Experiment
Overheard at JP Morgan's 25th Health Care Conference: Making Up for Lost Drugs: Pharma Attempts to Appease Investors
A New Approach to Repurposing: Ditch the Hypotheses
Accessing Pharma Assets: Having the Right People Helps
The New Out-Licensing Start-Ups: Securing Product Supply
No Dilution Necessary: The Promise of Project Financing
Symphony & Guilford Try Out Project Financing


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts